Strona główna・Stock List・REGENXBIO Inc

REGENXBIO Inc

Closed

SectorHealthcare

10.3 4.15

Buy Sell

Overview

Share price change

24h

Current

Min

9.23

Max

Key metrics
By Trading Economics
Income	-23M -90M
Sales	-24M 6.4M
EPS	-1.72
Profit margin	-1,408.588
Employees	371
EBITDA	-14M -77M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+160.78% upside

Dividends
By Acuity
Next Earnings	6 sie 2026

Market Stats
By TradingEconomics
Market Cap	101M 622M
Previous open	6.15
Previous close	10.3

News Sentiment

By Acuity

50%

151 / 340 Ranking in Healthcare

REGENXBIO Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

31 lip 2026, 19:36 UTC

Regenxbio Inc shares are lower, influenced by declines in the Biotechnology sector. The stock showed volatility, briefly rising earlier in the session.

30 lip 2026, 19:29 UTC

Regenxbio Inc shares are higher during Thursday's session, continuing an upward trend since Wednesday. The stock remains below its 20-day moving average.

29 lip 2026, 19:56 UTC

Macro Event

Regenxbio Inc is trading higher as the Federal Reserve maintains interest rates, reflecting heightened market sensitivity amid ongoing economic growth and geopolitical tensions.

28 lip 2026, 18:16 UTC

Regenxbio Inc shares are lower, continuing a three-day decline amid broader market pressures, including losses in Asian markets like the Nikkei 225 Index.

27 lip 2026, 19:36 UTC

Regenxbio Inc is trading higher during Monday's session, recovering from earlier declines. Broader market sentiment is influenced by a significant drop in oil prices.

24 lip 2026, 20:07 UTC

Regenxbio Inc shares are lower today, continuing a decline since Thursday's close. The stock remains below its 20-day moving average, indicating market weakness.

22 lip 2026, 18:26 UTC

Regenxbio Inc shares are lower amid geopolitical tensions and rising crude oil prices. Earlier in the session, shares briefly recovered but have since declined.

21 lip 2026, 19:31 UTC

Regenxbio Inc is higher during Tuesday's session, tracking the broader market's gains amid positive sentiment from recent earnings reports. No specific company news was identified.

20 lip 2026, 19:31 UTC

Event

News

Social Media

Regenxbio shares rise after positive long-term trial results for surabgene lomparvovec, showing sustained vision improvements in patients with retinal conditions.

Peer Comparison

Price change

REGENXBIO Inc Forecast

Price Target

By TipRanks

160.78% upside

12 Months Forecast

Average 25.27 USD 160.78%

High 45 USD

Low 10 USD

Based on 11 Wall Street analysts offering 12 month price targets forREGENXBIO Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

11 ratings

Buy

Hold

Sell

Based on 11 analysts giving stock ratings to REGENXBIO Inc - Dist in the past 3 months.

Sentiment

By Acuity

151 / 340 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About REGENXBIO Inc

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.